Feasibility of Semaglutide in Advanced Lung Disease
Recruiting · NCT05746039 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Pennsylvania
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
Who can take part
Inclusion criteria
- Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
- Age \> 18
- BMI \> 30 kg/m2
- Requires supplemental oxygen on exertion
- Stable treatment regimen X 90 days
- Use of disease-modifying therapy
Exclusion criteria
- Diabetes
- Pregnant or Breastfeeding
- Recent weight loss
- Recent or chronic GI complaints
- History of gastroparesis
- History of scleroderma
- Hospitalized at time of evaluation
- Use of weight loss medication in last 90 days
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
- Uncontrolled thyroid disease
- History of acute/chronic pancreatitis
- Prior suicide attempt
- Suicidal ideation in last 90 days
- Presence of a pacemaker or defibrillator
Where it is running
1 location listed across 1 US state.
- University of Pennsylvania Perelman School of Medicine - Philadelphia, Pennsylvania, United States